Swedish Orphan Biovitrum Stock Total Asset
| B6E Stock | EUR 26.86 0.00 0.00% |
Swedish Orphan Biovitrum fundamentals help investors to digest information that contributes to Swedish Orphan's financial success or failures. It also enables traders to predict the movement of Swedish Stock. The fundamental analysis module provides a way to measure Swedish Orphan's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Swedish Orphan stock.
Swedish |
Swedish Orphan Biovitrum Company Total Asset Analysis
Swedish Orphan's Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current Swedish Orphan Total Asset | 48.66 B |
Most of Swedish Orphan's fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Swedish Orphan Biovitrum is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
| Competition |
Based on the latest financial disclosure, Swedish Orphan Biovitrum has a Total Asset of 48.66 B. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers - Specialty & Generic industry. The total asset for all Germany stocks is 65.14% lower than that of the firm.
Swedish Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Swedish Orphan's direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Swedish Orphan could also be used in its relative valuation, which is a method of valuing Swedish Orphan by comparing valuation metrics of similar companies.Swedish Orphan is rated fourth in total asset category among its peers.
Swedish Fundamentals
| Return On Equity | 0.11 | |||
| Return On Asset | 0.0555 | |||
| Profit Margin | 0.14 % | |||
| Current Valuation | 6.67 B | |||
| Shares Outstanding | 295.99 M | |||
| Shares Owned By Insiders | 4.00 % | |||
| Shares Owned By Institutions | 69.59 % | |||
| Price To Earning | 18.28 X | |||
| Price To Book | 2.47 X | |||
| Price To Sales | 3.66 X | |||
| Revenue | 15.53 B | |||
| Gross Profit | 14.38 B | |||
| EBITDA | 5.72 B | |||
| Net Income | 2.68 B | |||
| Cash And Equivalents | 280.15 M | |||
| Cash Per Share | 1.04 X | |||
| Total Debt | 8.78 B | |||
| Debt To Equity | 39.80 % | |||
| Current Ratio | 0.75 X | |||
| Book Value Per Share | 3.55 X | |||
| Cash Flow From Operations | 5.47 B | |||
| Earnings Per Share | 0.93 X | |||
| Price To Earnings To Growth | 33.82 X | |||
| Number Of Employees | 1.56 K | |||
| Beta | 0.39 | |||
| Market Capitalization | 6.36 B | |||
| Total Asset | 48.66 B | |||
| Net Asset | 48.66 B |
About Swedish Orphan Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Swedish Orphan Biovitrum's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Swedish Orphan using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Swedish Orphan Biovitrum based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Swedish Stock
Swedish Orphan financial ratios help investors to determine whether Swedish Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Swedish with respect to the benefits of owning Swedish Orphan security.